Vaxart (VXRT) Stock Price, News & Analysis

Company Overview

Vaxart, Inc. is a clinical‐stage biotechnology company focused on the development of orally administered recombinant vaccines delivered in tablet form. Utilizing its proprietary VAAST™ (Vaccine‐Assisted Antigen Presentation System Technology) platform, Vaxart aims to stimulate both mucosal and systemic immune responses without the need for injections. The company’s approach is designed to simplify distribution logistics, eliminate cold‐chain requirements, and improve patient compliance by offering needle‐free vaccination options.

Vaxart’s pipeline includes oral vaccine candidates for respiratory and enteric diseases. Among its lead programs is an oral COVID‐19 vaccine candidate intended to bolster mucosal immunity at the point of viral entry. In addition, Vaxart is advancing oral formulations targeting influenza and norovirus, each intended to provide broad protection and ease of administration. The company has engaged in preclinical and clinical collaborations to assess immunogenicity, safety and potential for rapid scale‐up should regulatory approvals be obtained.

Founded in 2010 and headquartered in South San Francisco, California, Vaxart leverages a multidisciplinary team with expertise in virology, immunology and pharmaceutical development. The company has established manufacturing partnerships to support tablet formulation and has explored global distribution channels to address unmet vaccine needs in both developed and emerging markets. Vaxart’s leadership team is led by Chief Executive Officer Andrei Floroiu, whose prior roles include senior finance positions at public biotechnology companies, and Chief Scientific Officer Dr. Rich Malley, who brings extensive experience in vaccine research and development.

Key Stats

• Today's Range: $0.33 to $0.47
• 50-Day Range: $0.30 to $0.70
• 52-Week Range: $0.26 to $1.07
• Volume: 4.67 million shs
• Average Volume: 2.66 million shs
• Market Capitalization: $102.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.00
• Consensus Rating: Buy

Vaxart Stock Analysis - MarketRank™

Vaxart scored higher than 71% of companies evaluated by MarketBeat, and ranked 270th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Vaxart has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Vaxart has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Vaxart are expected to grow in the coming year, from ($0.39) to ($0.38) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vaxart is -1.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vaxart is -1.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Vaxart has a P/B Ratio of 1.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.37% of the float of Vaxart has been sold short.

Short Interest Ratio / Days to Cover

Vaxart has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vaxart has recently decreased by 96.08%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vaxart does not currently pay a dividend.

Dividend Growth

Vaxart does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.37% of the float of Vaxart has been sold short.

Short Interest Ratio / Days to Cover

Vaxart has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vaxart has recently decreased by 96.08%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 1.41

News Sentiment

Vaxart has a news sentiment score of 1.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.00 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Vaxart this week, compared to 2 articles on an average week.

Search Interest

8 people have searched for VXRT on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Vaxart to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Vaxart insiders have bought more of their company's stock than they have sold. Specifically, they have bought $49,000.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 2.90% of the stock of Vaxart is held by insiders.

Percentage Held by Institutions

Only 18.05% of the stock of Vaxart is held by institutions.

VXRT Stock Analysis - Frequently Asked Questions

How have VXRT shares performed this year?

Vaxart's stock was trading at $0.6621 at the beginning of 2025. Since then, VXRT stock has decreased by 32.4% and is now trading at $0.4478.

How were Vaxart's earnings last quarter?

Vaxart, Inc. (NASDAQ:VXRT) posted its quarterly earnings results on Tuesday, May, 13th. The biotechnology company reported ($0.07) EPS for the quarter, meeting the consensus estimate of ($0.07). The biotechnology company had revenue of $20.88 million for the quarter, compared to analyst estimates of $2.85 million. Vaxart had a negative trailing twelve-month return on equity of 91.89% and a negative net margin of 122.63%.
Read the conference call transcript.

When did Vaxart's stock split?

Vaxart shares reverse split on Wednesday, February 14th 2018.The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split.

How do I buy shares of Vaxart?

Shares of VXRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Vaxart own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vaxart investors own include Plug Power (PLUG), Workhorse Group (WKHS), FuelCell Energy (FCEL), Fortress Biotech (FBIO), Assertio (ASRT), Ovid Therapeutics (OVID) and KALA BIO (KALA).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VXRT
• Previous Symbol: NASDAQ:NABI
• CIK: 72444
• Web: www.vaxart.com
• Phone: (650) 550-3500
• Fax: 650-871-8580
• Employees: 120
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Vaxart: $3.00
• High Price Target: $4.00
• Low Price Target: $2.00
• Potential Upside/Downside: +569.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.27)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$66.95 million
• Net Margins: -122.63%
• Pretax Margin: -121.98%
• Return on Equity: -91.89%
• Return on Assets: -38.40%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.64
• Quick Ratio: 0.64

Sales & Book Value

• Annual Sales: $47.40 million
• Price / Sales: 2.16
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.26 per share
• Price / Book: 1.72

Miscellaneous

• Outstanding Shares: 228,310,000
• Free Float: 222,374,000
• Market Cap: $102.24 million
• Optionable: Optionable
• Beta: 1.14